Here are the 10-K annual reports from Bio-Rad Laboratories, Inc. (BIO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIO filings page.
Bio-Rad Laboratories, Inc. files its annual report describing a diversified life science and clinical diagnostics business with global reach. For the year ended December 31, 2025, the Life Science segment and Clinical Diagnostics segment generated approximately 40% and 60% of consolidated net sales, and about 40% of sales came from the U.S., with 60% from international markets.
The company highlights extensive regulatory, reimbursement, and cybersecurity exposure, along with supply chain and macroeconomic risks. Bio-Rad reports approximately 7,450 employees worldwide and continues to invest heavily in research and development. The report also details a significant strategic stake in Sartorius AG, with a fair value of $5,669.2 million as of December 31, 2025, and notes outstanding long-term debt of approximately $1.2 billion in senior notes and remaining authorization of $284.6 million under a share repurchase program.